Sartorius Stedim stock gains after HSBC lifts target to 240 EUR

Sartorius Stedim stock is trading slightly higher on September 1, 2026, after HSBC raised its target price to 240 EUR, with the shares hovering around 200 EUR on Tradegate and Euronext Paris.

Sartorius Stedim stock is trading around 200.40 EUR on Tradegate as of September 1, 2026, up about 1.83 percent from the previous closing price of 196.00 EUR, keeping the bioprocessing specialist in focus for investors.

HSBC target increase supports valuation

According to an analyst overview reported by MarketScreener on September 1, 2026, Sartorius Stedim Biotech shares recently traded at 199.50 EUR on a real time CBOE venue, corresponding to a daily gain of 1.50 percent and a year to date performance of about -6.00 percent.

A same day analyst roundup on a French financial portal notes that HSBC has maintained its buy recommendation on Sartorius Stedim Biotech while raising its target price from 230 EUR to 240 EUR, signaling a cautiously supportive stance on the companys earnings power and growth prospects. This target implies an upside of roughly 19.7 percent from the 200.40 EUR Tradegate quote on September 1, 2026.

Recent price performance and trading venues

Market data compiled by MarketScreener for real time Tradegate trading shows a Sartorius Stedim Biotech price of 200.40 EUR at 10:30:35 on September 1, 2026, with a five day performance of plus 3.09 percent and a decline of 5.88 percent since the start of the year.

A related chart comparison page on MarketScreener, based on CBOE data as of August 31, 2026, lists a closing level around 197.10 EUR, reflecting a five day gain of 2.63 percent and a year to date increase of 2.87 percent for that specific trading metric, highlighting that short term momentum has recently turned slightly positive even while longer term performance remains mixed.

Bioprocessing solutions as growth driver

Sartorius Stedim Biotech focuses on single use technologies, filtration systems and bioreactors that are used by pharmaceutical and biotech companies to produce biologic drugs and vaccines. The portfolio ranges from upstream processing equipment for cell culture to downstream solutions for purification, positioning the company as an important supplier to the global life sciences industry.

Stock level around 200 EUR on September 1, 2026

Based on the Tradegate quotation cited in the same day corporate news overview, Sartorius Stedim Biotech shares are priced at 200.40 EUR as of September 1, 2026 on the German Tradegate trading venue, slightly above the recent closing price of 196.00 EUR, while the primary listing remains on Euronext Paris under the DIM ticker.

Sartorius Stedim Biotech stock facts

• Company: Sartorius Stedim Biotech S.A.
• ISIN: FR0013154002
• Ticker: DIM
• Trading venue: Euronext Paris; Tradegate secondary listing
• Price (as of September 1, 2026): 200.40 EUR
• Sector / Industry: Life sciences tools and services / Bioprocessing
• Index membership: TecDAX via the parent group